Analysts Are Bullish on These Healthcare Stocks: HAE, RGNX


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Haemonetics Corp (NYSE: HAE) and RegenXBio (NASDAQ: RGNX) with bullish sentiments.

Haemonetics Corp (NYSE: HAE)

Morgan Stanley analyst David Lewis maintained a Buy rating on Haemonetics Corp (NYSE: HAE) today and set a price target of $100. The company’s shares closed yesterday at $82.55, close to its 52-week high of $82.70.

According to TipRanks.com, Lewis is a 4-star analyst with an average return of 11.9% and a 71.6% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Stryker Corporation, and Intuitive Surgical.

Haemonetics Corp has an analyst consensus of Moderate Buy, with a price target consensus of $85.50.

See today’s analyst top recommended stocks >>

RegenXBio (NASDAQ: RGNX)

Raymond James analyst Reni Benjamin maintained a Buy rating on RegenXBio (NASDAQ: RGNX) yesterday and set a price target of $45. The company’s shares closed yesterday at $39.65, close to its 52-week high of $42.

Benjamin observed:

“We are maintaining our Outperform rating for REGENXBIO. Today, after market close, the company reported 1Q18 results and provided an update on its pipeline. Key takeaways include: 1) all programs remain on track, with topline data from both the wet AMD and HoFH trials expected in late 2018; and 2) the two MPS programs are slated to dose the first patients in mid-2018. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $336 million pro forma, we continue to recommend REGENXBIO shares to risk-tolerant investors.”

According to TipRanks.com, Benjamin is a 3-star analyst with an average return of 2.1% and a 44.1% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Invivo Therapeutics Holdings, Bellicum Pharmaceuticals, and Asterias Biotherapeutics.

Currently, the analyst consensus on RegenXBio is Strong Buy and the average price target is $49.40, representing a 24.6% upside.

In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $48 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts